ISSN:
1432-1041
Keywords:
BIM 23014
;
Somatostatin analogue
;
growth hormone
;
GHRH test
;
OGTT
;
adverse effects
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary We have studied the pharmacokinetics and the effects of BIM 23014 (BIM), a new, long-acting octapeptide somatostatin analogue, on basal and stimulated GH secretion in normal men. BIM 250 μg sc significantly reduced a GHRH-induced increase in plasma GH. The continuous sc administration of BIM for 24 h dramatically blunted spontaneous GH secretion; 2000 and 3000 μg daily reduced GH secretion to a greater extent than 1000 μg daily. During these experiments a significant negative correlation (r−0.66) was found between plasma GH and BIM levels. Acute sc administration of 1000 μg BIM significantly reduced the rise in plasma GH observed in the second part of the oral glucose tolerance test. Plasma BIM levels peaked around 30 min, and the elimination half life was 90 min. Plasma BIM levels were below 1 ng/ml 6 h after the injection of 1000 μg BIM, and at that time GH started to rise again. We conclude that BIM 23014 250 to 1000 μg sc is able to reduce the plasma GH response to GHRH or to the fall in glucose following an oral glucose tolerance test; a constant infusion of BIM, in doses 1000 μg daily, dramatically suppresses spontaneous GH secretion; 2000 μg/day by chronic subcutaneous infusion was the most effective dose of BIM in the suppression of GH secretion, and was associated only with minor adverse effects.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00315353
Permalink